Holen Sie sich die Stockscreener-App
174.00
1.30%
2.24
Vorhandelsmarkt:
174.00
Schlusskurs vom Vortag:
$171.76
Offen:
$171.86
24-Stunden-Volumen:
671.29K
Relative Volume:
0.53
Marktkapitalisierung:
$14.05B
Einnahmen:
$8.19B
Nettoeinkommen (Verlust:
$758.19M
KGV:
18.95
EPS:
9.18
Netto-Cashflow:
$1.06B
1W Leistung:
-3.47%
1M Leistung:
-6.96%
6M Leistung:
-8.24%
1J Leistung:
-46.63%
1-Tages-Spanne:
$169.99
$174.73
1-Wochen-Bereich:
$169.99
$181.51
52-Wochen-Spanne:
$125.10
$328.04
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ICLR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
174.00 | 13.36B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
488.12 | 184.46B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.00 | 147.69B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
640.86 | 51.34B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.69 | 33.60B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
188.80 | 31.92B | 15.70B | 1.24B | 2.01B | 6.91 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
ICON plc Releases Interim Financial Statements for 2025 - TipRanks
ICON Properties Plc (Malawi) declared a final dividend of 0.15 MWK per share - AfricanFinancials
Earnings call transcript: ICON plc beats Q2 2025 earnings expectations - Investing.com
Citi Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $200 - 富途牛牛
ICON plc Halts COVID Vaccine Study Due to BARDA Stop Work Notice - AInvest
Healthcare Sector Rebound: Is Now the Time to Buy High-Quality CROs Like ICON? - AInvest
ICON suspends COVID vaccine study after BARDA notice - MSN
Icon Plc (NASDAQ:ICLR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Icon Suspends COVID Vaccine Study After BARDA Notice, Impacting H2 2025 Revenue - AInvest
ICON plc Halts COVID Vaccine Study Following BARDA Notice - MSN
Icon PLC Shares Jump 4.26% on $250M Volume as Analysts Target 25% Gains Despite 462nd Rank - AInvest
BARDA Stops ICON COVID Vaccine Study, Company Suspends New Enrollments - AInvest
ICON suspends COVID vaccine study after BARDA notice to sponsor - Seeking Alpha
ICON plc Provides Update on Vaccine Study - MarketScreener
ICON (ICLR) Fell Along with Broader CROs - Insider Monkey
ICON plc (ICLR) Fell due to Persistent Volatility in the Clinical Development Market - Insider Monkey
ICON plc (ICLR) stock fell due to persistent volatility in the clinical development market. - AInvest
Arkadios Wealth Advisors Purchases 6,666 Shares of Icon Plc (NASDAQ:ICLR) - Defense World
Fund Update: First Pacific Advisors, LP added 417,173 shares of ICON PLC ($ICLR) to their portfolio - Quiver Quantitative
ICON Plc’s Earnings Call: Balancing Achievements and Challenges - TipRanks
ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! - smartkarma.com
ICON Plc's Q2 Earnings Call: Balancing Growth and Challenges - AInvest
Deutsche Bank Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $210 - 富途牛牛
Leerink Partners Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape By Investing.com - Investing.com India
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape - Investing.com
ICON's Intrinsic Value Estimated at $278, 33% Undervalued by Current Share Price - AInvest
Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio? - Benzinga
Icon price target raised to $225 from $173 at Mizuho - TipRanks
ICON plc Q2 2025 Financial Results: Revenue Up 0.8%, Net Income Rises 30.7% - AInvest
UBS Raises Icon PLC Price Target to $240, Maintains 'Buy' Rating - AInvest
Icon PLC (ICLR) Sees Price Target Boost Amid Stable Booking Trends - AInvest
ICON plc Reports Strong Q2 2025 Financial Results - The Globe and Mail
ICON plc Expands Share Repurchase Program and Resumes COVID Vaccine Study - The Globe and Mail
ICON plcOrdinary Shares (Nasdaq:ICLR) Stock Quote - FinancialContent
Evercore Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $209 to $240 - 富途牛牛
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Wins - GuruFocus
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha - GuruFocus
Icon plc's Shares Surge 17.2% Amid Investor Optimism - AInvest
Icon Plc Announces Kedrion IVIg 10% Study for Chronic ITP: Market Implications - AInvest
ICON Expects $8B in Revenue for Full Year, Driven by Biotech Wins and Pharma Partnerships - AInvest
ICON plc Announces Successful AGM Resolutions - The Globe and Mail
ICON Stock Surge: Future Safe or Risky? - StocksToTrade
ICON’s Unexpected Surge: What’s Behind the Jump? - timothysykes.com
ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery - Benzinga
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $170 to $224 - 富途牛牛
Icon plc (ICLR) Shares Surge Over 17% Amid Investor Optimism | ICLR Stock News - GuruFocus
Icon Plc’s New Study on Kedrion IVIg 10% for Chronic ITP: What Investors Need to Know - TipRanks
ICON’s Earnings Beat and Strategic Moves: A Market Outlook - StocksToTrade
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):